Suven Pharmaceuticals Limited has informed the Exchange about allotment of shares pursuant to the scheme of amalgamation
COHANCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.3 pts more than Nifty Smallcap 250 and 1.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Suven Pharmaceuticals has allotted 12,80,02,184 equity shares of face value Re. 1 each to shareholders of Cohance Lifesciences Limited (Transferor Company) as part of their approved merger. The shares were issued at an exchange ratio of 11 shares of Suven for every 295 shares held in Cohance. The scheme was approved by NCLT Mumbai on March 27, 2025. Additionally, the company has changed its name from Suven Pharmaceuticals Limited to Cohance Lifesciences Limited post-merger. The newly allotted shares will be listed on BSE and NSE and will rank equally with existing shares.
This completes the merger process — Cohance shareholders now hold shares in the renamed entity (Cohance Lifesciences Limited, formerly Suven). Existing Suven shareholders see dilution but gain exposure to the combined business. Shareholders should expect updated shareholding patterns and trading under the new name shortly.